Walmart Slides Most Since 2022 on Slowing US Sales Growth

Walmart’s earnings miss is attributed to weaker pharmaceutical sales, pressured by new federal drug negotiations designed to lower prices. The article suggests the headwind is likely to persist for both the company and investors, keeping US sales growth concerns alive. Walmart may partially offset this by using competitive pricing to attract customers, though near-term sentiment remains cautious.

Analysis

The market should treat this less as a fundamental break in the core retail franchise and more as a mix problem: pharmacy is a traffic driver but not a profit engine, so weakness there can distort reported sales growth without implying the core grocery/consumables engine is losing share. The real question is whether management uses pricing to defend trips and basket, which would support comps but compress margin dollars, or whether they allow pharmacy softness to bleed into the broader US growth narrative.

Second-order losers are the more pharmacy-dependent channels: drugstores and PBM-linked models have more earnings leverage to any sustained repricing, while a scaled retailer can absorb lower drug revenue and potentially pick up share with competitive cash pricing. Over 1-3 months, the stock will trade on whether management can point to non-pharmacy comp acceleration; over 6-18 months, policy-driven drug deflation should be more of a mix/margin headwind than a true demand shock. The thesis breaks if US comps reaccelerate without incremental margin sacrifice, or if the pharmacy drag proves one-off rather than persistent.

The contrarian read is that investors may be overweighting the negative optics of lower pharmacy dollars and underweighting the traffic benefit from cheaper access to medications. If the retailer leans into price leadership, the issue may actually support household budget relief and reinforce its value proposition versus smaller grocers and regional chains. The signal to watch is whether the next few quarters show stable gross margin despite softer pharmacy sales; that would argue the concern is being monetized rather than amplified.

Key Decisions for Investors

• Do not press a standalone short in WMT here; wait for either a deeper multiple reset or a second quarter of US comp underperformance before treating this as a durable earnings miss.
• Use any post-earnings weakness to build a tactical long in WMT over a 1-3 month horizon if management confirms grocery/fresh traffic is offsetting pharmacy mix drag; target a rebound if gross margin remains stable.
• Pair trade: long WMT / short a pharmacy-heavy retail proxy such as WBA or CVS over the next 1-3 months if policy-driven drug repricing continues, since the margin impact should be more painful outside a diversified format.
• Set an alert on WMT US comps and gross margin for the next print: if sales growth improves but margin falls >20-30 bps, the market may start treating this as a defensive share-gain story rather than a true earnings problem.
• If the stock sells off 5%+ on headline concern alone, consider a call spread rather than equity add: the upside case is a sentiment reset if management shows that lower drug prices are boosting traffic, not just reducing revenue dollars.